Kerstin Wolk, Dagmar Wilsmann-Theis, Nessr Abu Rached, Giorgia Cugno, Rotraut Moessner, Christian Kromer, Falk G Bechara, Katharina Assaf, Wiebke K Peitsch, Lisa C Schneider, Andreas Happ, Valentina Siddi, Diana Kubitzki, Durdana Groß, Markus Friedrich, Staffan Vandersee, Khusru Asadullah, Sylke Schneider-Burrus, Georgios Kokolakis, Robert Sabat
{"title":"Determinants of Satisfaction with Medical Care for Hidradenitis Suppurativa: Results from a Multicentre Survey in Germany.","authors":"Kerstin Wolk, Dagmar Wilsmann-Theis, Nessr Abu Rached, Giorgia Cugno, Rotraut Moessner, Christian Kromer, Falk G Bechara, Katharina Assaf, Wiebke K Peitsch, Lisa C Schneider, Andreas Happ, Valentina Siddi, Diana Kubitzki, Durdana Groß, Markus Friedrich, Staffan Vandersee, Khusru Asadullah, Sylke Schneider-Burrus, Georgios Kokolakis, Robert Sabat","doi":"10.1007/s13555-025-01558-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with considerable physical and psychosocial distress. Recent studies have reported low levels of satisfaction among patients with HS regarding the medical care of their condition. The objective of the study was to identify modifiable determinants of low satisfaction with HS care from both patient and dermatologist perspectives.</p><p><strong>Methods: </strong>This prospective, questionnaire-based survey was conducted among patients with HS and, for comparison, among those with psoriasis, as well as their treating dermatologists, in 20 dermatological centres in Germany.</p><p><strong>Results: </strong>A total of 257 patients and 76 dermatologists participated in the study. The proportion of patients reporting high satisfaction with care for their skin disease (scores > 8 on a 0-10 scale) was 30.7% for HS and 69.4% for psoriasis (P < 0.001). The proportion of dermatologists highly satisfied with medical care for HS and psoriasis was 0.0% and 38.9%, respectively (P < 0.001). Multiple regression modelling revealed that satisfaction with pharmacotherapy was the primary predictor of medical care satisfaction for both patients and dermatologists. Experience with systemic antibiotics was associated with lower patient satisfaction regarding pharmacotherapy, while satisfaction tended to be higher when patients had experienced therapy with biologics. Another significant determinant of patient satisfaction with medical care was the provision of information about HS by dermatologists, which was linked to consultations occurring at least quarterly and lasting ≥ 20 min. No association was observed between disease severity and the identified determinants of patient satisfaction with medical care. Dermatologists' satisfaction with medical care was additionally linked with the perceived availability of referral options to other dermatological facilities.</p><p><strong>Conclusions: </strong>Improvements in patient satisfaction with HS care may be achieved through enhanced patient education about the disease and regular dermatologist consultations; however, optimal HS management ultimately requires effective pharmacological treatment.</p><p><strong>Trial registration: </strong>drks.de, DRKS00031572.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01558-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with considerable physical and psychosocial distress. Recent studies have reported low levels of satisfaction among patients with HS regarding the medical care of their condition. The objective of the study was to identify modifiable determinants of low satisfaction with HS care from both patient and dermatologist perspectives.
Methods: This prospective, questionnaire-based survey was conducted among patients with HS and, for comparison, among those with psoriasis, as well as their treating dermatologists, in 20 dermatological centres in Germany.
Results: A total of 257 patients and 76 dermatologists participated in the study. The proportion of patients reporting high satisfaction with care for their skin disease (scores > 8 on a 0-10 scale) was 30.7% for HS and 69.4% for psoriasis (P < 0.001). The proportion of dermatologists highly satisfied with medical care for HS and psoriasis was 0.0% and 38.9%, respectively (P < 0.001). Multiple regression modelling revealed that satisfaction with pharmacotherapy was the primary predictor of medical care satisfaction for both patients and dermatologists. Experience with systemic antibiotics was associated with lower patient satisfaction regarding pharmacotherapy, while satisfaction tended to be higher when patients had experienced therapy with biologics. Another significant determinant of patient satisfaction with medical care was the provision of information about HS by dermatologists, which was linked to consultations occurring at least quarterly and lasting ≥ 20 min. No association was observed between disease severity and the identified determinants of patient satisfaction with medical care. Dermatologists' satisfaction with medical care was additionally linked with the perceived availability of referral options to other dermatological facilities.
Conclusions: Improvements in patient satisfaction with HS care may be achieved through enhanced patient education about the disease and regular dermatologist consultations; however, optimal HS management ultimately requires effective pharmacological treatment.
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
